Seeking Collaborative Partners to Advance Human Genomic Discoveries in Health and Disease

Regeneron Genetics Center® (RGC) is seeking collaborators with well‑characterized human subject cohorts for specific diseases. The focus is on accessing human biospecimens appropriately consented for genetic sequencing, alongside de‑identified clinical and phenotypic data, for internal research and development purposes. In exchange, RGC will generate research‑use‑only genetic sequencing data and return all sequencing data to the collaborator to support their non‑profit research.

Approaches of Interest:

• RGC is open to all disease areas, with a particular focus on oncology, immunological, neurological and psychiatric, ophthalmologic, and cardiovascular and metabolic disorders. Please refer to the submission form for further details 
• Ideal applicants may demonstrate strengths across areas such as sample size, availability of appropriate controls, depth of phenotypic data, genetic diversity, availability of serum/plasma in addition to DNA
• Most or all of the samples should be banked (rather than prospective) 
• Data derived from individual demographic groups—for example, women, or specific local demographic or genetic backgrounds—are also of interest 

Submission Information

Applicants should complete the submission form which should contain a brief, non‑confidential overview of your proposal, demonstrating how the RFP requirements are satisfied by your approach. Proposals should outline any resources required to enable a collaboration. To submit your proposal, please visit our website, register, and submit your application form under the appropriate Connect campaign. The RGC requires that Informed Consent signed by research participants is appropriate for the proposed collaboration and that the IRB approval is obtained before commencing a collaboration.

Opportunity for Collaboration

Each selected partner will receive in‑kind DNA sequencing (whole‑exome sequencing and genome‑wide genotyping) performed by RGC, with all sequencing data returned for internal research use and non‑commercial sharing. Publication of results is encouraged following a brief advance review period. 

RGC will provide tubes for sample transfer, cover shipping costs, and generate sequencing data at its expense. Collaboration‑specific operational funding may be provided under mutually agreed terms, dependent on cohort uniqueness, size, and phenotypic depth. Optional additional in‑kind molecular assays and future collaboration opportunities may be considered on a case‑by‑case basis.